

Peter Kong, CFA

peter.kong@clsa.com
+60 3 2056 7877

25 August 2017

Malaysia

Infrastructure

Reuters SCOG.KL
Bloomberg SCGB MK

Priced on 24 August 2017

KLSE Comp @ 1,775.5

12M hi/lo RM2.36/1.59

12M price target RM2.75
±% potential +19%

Shares in issue 1,292.9m
Free float (est.) 45.6%

Market cap US\$701m

3M average daily volume
RM3.0m (US\$0.7m)


Foreign s'holding 9.0%

Major shareholders

Sunway Berhad 54.4%
Sungei Way Corp Sdn Bhd 10.1%

Stock performance (%)

	1M	3M	12M
Absolute	12.6	12.1	41.5
Relative	11.8	11.8	34.0
Abs (US\$)	12.7	12.4	33.1



Source: Bloomberg

www.clsa.com

Still a shining star

Construction segment's best pre-tax profit since listing

Faster QoQ job progress and better margins propelled this pure-play contractor to its best quarterly showing for its construction segment since listing, and a 18% YoY earnings improvement for SunCon overall in 1H17. However, SunCon's earnings for 1H17 formed only 42%/46% of ours/street's full-year estimates as its pre-cast segment was weighed down by slower progress by its customers (main contractors); this we think would be a near-term irritation. Still, margins that have been better than expected, leading us to upgrade earnings by 7%/8% for 18CL/19CL. Reiterate BUY with a higher TP of RM2.75 (was RM2.55).

Best construction quarter since listing; RM1bn of jobs secured

The RM1bn of jobs secured YTD (51% in-house, 49% external) has met 45% of our RM2.2bn replenishment target. With a RM14bn tender book, for its near-term pipeline, we fancy SunCon's chances to be among winners for the RM9bn Light Rail Transit 3, where it has submitted a few bids and boasts a good track record (bagged RM3.4bn of rail jobs in 6 years). Meanwhile, no shortage of in-house prospects - its parent is adding five hospitals over the next 2-3 years which should keep such work flowing in.

Delayed gratification in pre-cast as revenue recognition slowed

Pre-tax profit for pre-cast segment came in only at RM6m in 2Q17 - low versus historical norms - despite slightly enlarged order book (at RM251m). While results for 17CL will be dampened, we expect the fulfilling of the backlog to create a slight bumper effect in 2018. On balance, pre-tax profit margin in this division still stayed robust at 22% for 1H17.

Enhanced margins and cashflow

Stripping out arbitration gains, SunCon's pre-tax profit margin still came in at 9.7% for 1H17 (above our estimate of 8.4% for 2017). SunCon's operating cashflow improved in 1H17, augmenting its net cash pile, which also saw the declaration of an interim dividend equivalent to 54% of profits for 1H17.

Upgraded TP; earnings delivery supports price gains

Given the slow revenues for its pre-cast division, we lower our earnings for 17CL, but steadily improving construction margins on existing jobs lead us to nudge up earnings for 2018 and 2019. Our revised TP of RM2.75 is arrived at with an unchanged multiple of 16.7x PE on 18CL earnings, ie, at 1 sd above 3-year sector average.

Financials

Year to 31 December	15A	16A	17CL	18CL	19CL
Revenue (RMm)	1,917	1,789	2,321	2,839	2,897
Rev forecast change (%)	-	-	(7.7)	(3.0)	(8.1)
Net profit (RMm)	127	124	157	210	222
NP forecast change (%)	-	-	(7.1)	7.6	8.4
EPS (sen)	9.8	9.6	12.1	16.3	17.2
CL/consensus (12) (EPS%)	-	-	101	125	128
EPS growth (% YoY)	39.4	(2.9)	27.0	34.1	5.7
PE (x)	23.6	24.3	19.1	14.2	13.5
Dividend yield (%)	1.7	2.2	3.2	3.7	3.9
ROE (%)	30.6	26.2	30.0	34.9	31.5
Net debt/equity (%)	(56.2)	(66.7)	(66.1)	(70.3)	(69.6)

Source: CLSA

Figure 1


SunCon: Financials

FYE 31 Dec (RM m)	1H17	1H16	YoY % Chg	2Q17	1Q17	QoQ % Chg	Remarks
Revenue	836.8	854.6	(2%)	417.2	419.5	(1%)	Pre-cast concrete segment revenues dipped 56% QoQ in 2Q17
Operating expenses	(760.6)	(801.1)	(5%)	(380.5)	(380.1)	0%	
Other income	5.5	4.7	16%	5.0	2.6	91%	
Ebitda	102.1	92.5	10%	50.9	51.2	(1%)	Higher margins led to a 10% increase in Ebitda YoY despite lower revenues
Depreciation	(18.3)	(19.5)	(6%)	(9.1)	(9.1)	0%	
Ebit	83.8	73.0	15%	41.7	42.1	(1%)	
Interest income	5.5	4.7	16%	2.3	3.2	(28%)	
Interest expense	(2.3)	(2.1)	12%	(1.3)	(1.1)	18%	Given its net cash position, SunCon pays very minimal interest
Pre-tax profit	86.9	75.6	15%	42.8	44.2	(3%)	For 1HFY17, pre-tax profit would have increased 7% if an arbitration gain in 1H17 of RM6 million was excluded
Tax	(15.6)	(15.3)	2%	(6.1)	(9.5)	(36%)	
Effective tax rate	17.9%	20.2%	(11%)	14.2%	21.6%		
Minority interest	0.1	0.0		0.1	0.0		
Net profit	71.4	60.3	18%	36.8	34.7	6%	
EPS (sen)	5.52	4.67	18%	2.84	2.68	6%	
EBIT margin	10.0%	8.5%		10.0%	10.0%		
PBT margin	10.4%	8.8%		10.3%	10.5%		For 2 consecutive quarters, pre-tax profit margin hovered at around 10.5%

Source: CLSA, Company

Figure 2


Pre-tax profit for construction and pre-cast concrete division – Construction picking up the slack



Source: CLSA, Company

Figure 3

Pre-tax margins for construction continued to rise while that for pre-cast concrete maintained above 20%



Source: CLSA, Company

Rising construction earnings and margin; best quarter since listing

Sunway’s construction division delivered RM36.4m of pre-tax profits, its best showing with margins widening to 9.4% (inclusive arbitration gains), and is on a rising trend (see Figure 3). We believe this indicates that its key jobs are progressing well. Based on outstanding value of key large jobs, the Klang Valley Mass Rapid Transit Line 2 package V201 and Putrajaya Parcel F (that form close to half its order book) are only 20% and 34% complete respectively, suggesting good margins are likely to stay. That the major holidays (Chinese New Year and Eid) took place in 1H17 also suggests higher tendency for more work progress in 2H17.

Figure 4

SunCon's key outstanding jobs

RM million	Contract sum	Outstanding Value	% Complete	Completion
Putrajaya Parcel F	1,610	1,064	34%	3Q2018
MRT V201	1,213	974	20%	2Q2021
Sunway Serene - Serviced Residences	449	449	0%	4Q2020
Suway Medical Center 4	428	394	8%	4Q2018
International School of Kuala Lumpur	268	202	25%	2Q2018
KLCC (NEC + Package 2 & 2a)	646	170	74%	4Q2018
Gas district cooling	152	148	3%	3Q2018
Other construction work		626		
Pre-cast		251		
Total		4,278		

Source: CLSA, Company

Parent's healthcare wave a promising prospect

Prospects abound – externally and in-house


SunCon's parent, Sunway Berhad, has announced its intention to expand to hospitals to Penang (2 hospitals), Damansara, Johor and Ipoh. Having been involved in both Sunway Berhad's hospitals so far – in Cheras and in Bandar Sunway – we think SunCon has an upper hand in securing such rollouts. Total value that Sunway Berhad would be investing is RM1bn, of which a majority portion would likely be construction costs.

Several bids for LRT 3

According to Sunway, it has put in several bids for the LRT 3 project, including for the longest sections, which should increase its chances of bagging at least one of the infrastructure parcels. It has strong credentials in rail related work to back, where over the past six years, SunCon has clinched a total of RM3.4bn of such jobs.

Figure 5


Rail related jobs in past years for SunCon



Source: CLSA, Company

Figure 6

Steel price movements



Source: CLSA, Company


Rising steel prices but key jobs have some insulation

Steel prices which have jumped recently may adversely impact construction players. We highlight that 29% of its outstanding order book is insulated from such price volatilities given pass-through clauses for the Mass Rapid Transit Line 2 project (22%) and its Singapore pre-cast business (7%). Further, in another large job, Putrajaya Parcel F (25% of outstanding order book), a portion of steel requirements were procured earlier (job was secured in late 2015) which provides margin buffer to the project. As a practise, we

understand that SunCon typically locks in future steel requirements for the next 6 months.

Figure 7


Pre-cast order book – mild increase



Source: CLSA, Company

Figure 8

Steel prices trend show quick increase recently



Source: CLSA

Slow progress by main contractor impeded pre-cast work

Overall demand resilient

Still valuing SunCon at +1sd above 3-year mean sector PB

Earnings revised lower for 17CL

We think pre-cast segment will play catch up

Slow progress by main contractor in building Singapore’s Housing Development Board flat units caused a slowdown in delivery and revenue recognition for SunCon. We think that with the fulfilling of orders will occur in the future and have a small bumper effect on earnings YoY for 18CL. Nevertheless we observe that margins stay solid at 20% for 2Q17 in this segment helped by closure of Tampines plant in Singapore and now operating out of Senai and Iskandar in Johor (with a total capacity of 156,600m3).

Overall demand for SunCon’s pre-cast products is largely dictated by Singapore’s Housing and Development Board (HDB) which we view to be resilient. Having launched 12,755 units of build-to-order flat units up to early August and with an upcoming exercise to offer another 4,800 units in November, total supplied units by HDB are likely to closely match the 17,891 units seen in 2016.

Reiterate BUY; raise TP

We continue to like SunCon as a pure-play contractor with prospects of padding up jobs from both in-house and external sources; in house-jobs currently form 31% of total order book. It also has the safety of a strong cashflow generation against a low debt, which warrants a premium to sector average valuation in our view. We value SunCon at 16.7x PE, which is equivalent to 1sd above sector 3-year mean PE.

As profit margins on existing jobs have exceeded our estimates, we revise upwards the expectation of profit margins of existing large jobs and contracts to be secured. At the same time, we lower the expected revenue and earnings for 2017 to reflect slow progress in pre-cast deliveries which we believe will play catch up.

SunCon is trading at 15.8 times forward PE, which we believe is supported by its strong prospects and earnings growth

Figure 9

Summary of changes

		17CL	18CL	19CL
Pre-tax profit margins (%)	Previous	8.4%	8.4%	8.4%
	Revised	8.5%	9.3%	9.5%
Net profit (RM mn)	Previous	169	196	205
	Revised	157	210	222

Source: CLSA

Figure 10

SunCon's forward PE



Source: CLSA

Valuation details

We value SunCon using the price-earnings multiple approach. Its target price is derived from 16.7x 18CL earnings, which is based on 1sd above the 3-year construction sector mean forward PE ratio; this is still below the same ratio for heavyweights Gamuda and IJM, but above its mid-cap peers. We accord premium valuations over mean in our calculations to reflect its robust ROEs of more than 20%, strong cashflow generation backed by steady job orders from both internal and external sources. We further note that in our valuations, we have not incorporated benefit from its consistent net cash position.

Investment risks

The investment risks for SunCon mainly stem from construction risk. Specific risk to our estimates would be lower-than-expected margins (below 5-8%) or amount of projects secured falls below our expectation, either due to inability to secure projects or caused by delay on project roll-out. The increase in steel prices beyond anticipated will also creep into margins as SunCon hedges steel needs for a future 6-month period. On the pre-cast segment, risks to our earnings will be erosion of its currently-strong margins of 20% and/or the inability to retain customers due to the shift in its plant location (from Singapore to Malaysia) causing a slowdown in orders. SunCon is also susceptible to risk facing the construction industry in general, which includes the risk of disputes and ensuing lengthy negotiations which is not uncommon, not to mention the fluctuations in raw materials and availability of labour.

Summary financials

Year to 31 December	2015A	2016A	2017CL	2018CL	2019CL
Summary P&L forecast (RMm)					
Revenue	1,917	1,789	2,321	2,839	2,897
Op Ebitda	178	188	246	317	334
Op Ebit	136	149	190	256	269
Interest income	8	10	12	13	15
Interest expense	(4)	(6)	(5)	(5)	(5)
Other items	-	0	-	-	-
Profit before tax	141	154	196	263	278
Taxation	(13)	(30)	(39)	(53)	(56)
Minorities/Pref divs	(1)	0	0	0	0
Net profit	127	124	157	210	222
Summary cashflow forecast (RMm)					
Operating profit	136	149	190	256	269
Operating adjustments	(3)	(22)	0	0	0
Depreciation/amortisation	42	39	57	61	66
Working capital changes	65	(59)	(49)	(38)	(72)
Net interest/taxes/other	(8)	(33)	(39)	(53)	(56)
Net operating cashflow	232	75	158	227	207
Capital expenditure	(39)	(19)	(30)	(30)	(30)
Free cashflow	193	56	128	197	177
Acq/inv/disposals	40	13	-	-	-
Int, invt & associate div	(57)	89	12	13	15
Net investing cashflow	(56)	83	(18)	(17)	(15)
Increase in loans	2	0	-	-	-
Dividends	(70)	(84)	(97)	(110)	(116)
Net equity raised/other	0	-	0	0	0
Net financing cashflow	(68)	(84)	(97)	(110)	(116)
Incr/(decr) in net cash	107	74	43	99	75
Exch rate movements	5	2	(5)	(6)	(5)
Opening cash	278	390	465	503	597
Closing cash	390	465	503	596	667
Summary balance sheet forecast (RMm)					
Cash & equivalents	390	466	503	597	666
Debtors	579	732	776	949	968
Inventories	17	24	0	0	0
Other current assets	230	220	233	233	233
Fixed assets	162	138	112	81	45
Intangible assets	4	6	6	6	6
Other term assets	14	11	11	11	11
Total assets	1,397	1,597	1,640	1,877	1,930
Short-term debt	137	137	137	137	137
Creditors	796	955	949	1,085	1,032
Other current liabs	9	11	-	0	-
Long-term debt/CBs	-	-	-	-	-
Provisions/other LT liabs	4	1	1	1	1
Minorities/other equity	1	1	1	1	1
Shareholder funds	451	493	553	654	760
Total liabs & equity	1,397	1,597	1,640	1,877	1,930
Ratio analysis					
Revenue growth (% YoY)	1.9	(6.7)	29.8	22.3	2.0
Ebitda growth (% YoY)	10.2	5.7	30.8	28.8	5.4
Ebitda margin (%)	9.3	10.5	10.6	11.2	11.5
Net profit margin (%)	6.6	6.9	6.8	7.4	7.7
Dividend payout (%)	40.6	52.3	61.8	52.2	52.3
Effective tax rate (%)	9.2	19.5	20.0	20.0	20.0
Ebitda/net int exp (x)	-	-	-	-	-
Net debt/equity (%)	(56.2)	(66.7)	(66.1)	(70.3)	(69.6)
ROE (%)	30.6	26.2	30.0	34.9	31.5
ROIC (%)	59.1	65.5	86.0	107.0	100.9
EVA@/IC (%)	48.2	54.6	75.1	96.1	90.0

Source: CLSA



Research subscriptions

To change your report distribution requirements, please contact your CLSA sales representative or email us at cib@clsa.com. You can also fine-tune your Research Alert email preferences at https://www.clsa.com/member/tools/email_alert/.

Companies mentioned


SunCon (SCGB MK - RM2.32 - BUY)
Sunway (N-R)

Analyst certification

The analyst(s) of this report hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this research report.

Important disclosures

Recommendation history of Sunway Construction Group Bhd SCGB MK



Date	Rec	Target	Date	Rec	Target
LATEST	BUY	2.75	18 May 2017	BUY	2.55

Source: CLSA

The policy of CLSA (which for the purpose of this disclosure includes its subsidiary CLSA B.V.) and CL Securities Taiwan Co., Ltd. ("CLST") is to only publish research that is impartial, independent, clear, fair, and not misleading. Analysts may not receive compensation from the companies they cover. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to a research report as below. This research disclosure should be read in conjunction with the research disclaimer as set out at www.clsa.com/disclaimer.html and the applicable regulation of the concerned market where the analyst is stationed and hence subject to. This research disclosure is for your information only and does not constitute any recommendation, representation or warranty. Absence of

a discloseable position should not be taken as endorsement on the validity or quality of the research report or recommendation.

To maintain the independence and integrity of CLSA's research, our Corporate Finance, Sales Trading and Research business lines are distinct from one another. This means that CLSA's Research department is not part of and does not report to CLSA Corporate Finance (or "investment banking") department or CLSA's Sales and Trading business. Accordingly, neither the Corporate Finance nor the Sales and Trading department supervises or controls the activities of CLSA's research analysts. CLSA's research analysts report to the management of the Research department, who in turn report to CLSA's senior management.

CLSA has put in place a number of internal controls designed to manage conflicts of interest that may arise as a result of CLSA engaging in Corporate Finance, Sales and Trading and Research activities. Some examples of these controls include: the use of information barriers and other information controls designed to ensure that confidential information is only shared on a "need to know" basis and in compliance with CLSA's Chinese Wall policies and procedures; measures designed to ensure that interactions that may occur among CLSA's Research personnel, Corporate Finance and Sales and Trading personnel, CLSA's financial product issuers and CLSA's research analysts do not compromise the integrity and independence of CLSA's research.

Neither analysts nor their household members/associates may have a financial interest in, or be an officer, director or advisory board member of companies covered by the analyst unless disclosed herein. In circumstances where an analyst has a pre-existing holding in any securities under coverage, those holdings are grandfathered and the analyst is prohibited from trading such securities.

Unless specified otherwise, CLSA/CLST did not receive investment banking/non-investment banking income from, and did not manage/co-manage a public offering for, the listed company during the past 12 months, and it does not expect to receive investment banking compensation from the listed company within the coming three months. Unless mentioned otherwise, CLSA/CLST does not own a material discloseable position, and does not make a market, in the securities.

As analyst(s) of this report, I/we hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this report or to any investment banking relationship with the subject company covered in this report (for the past one year) or otherwise any other relationship with such company which leads to receipt of fees from the company except in ordinary course of business of the company. The analyst/s also state/s and confirm/s that he/she/they has/have not been placed under any undue influence, intervention or pressure by any person/s in compiling this research report. In addition, the analysts included herein attest that they were not in possession of any material, nonpublic information regarding the subject company at the time of publication of the report. Save from the disclosure below (if any), the analyst(s) is/are not aware of any material conflict of interest.

Key to CLSA/CLST investment rankings: BUY: Total stock return (including dividends) expected to exceed 20%; O-PF: Total expected return below 20% but exceeding market return; U-PF: Total expected return positive but below market return; SELL: Total return expected to be negative. For relative performance, we benchmark the 12-month total forecast return (including dividends) for the stock against the 12-month forecast return (including dividends) for the market on which the stock trades.

We define as "Double Baggers" stocks we expect to yield 100% or more (including dividends) within three years at the time the stocks are introduced to our "Double Bagger" list. "High Conviction" Ideas are not necessarily stocks with the most upside/downside, but those where the Research Head/Strategist believes there is the highest likelihood of positive/negative returns. The list for each market is monitored weekly.

Overall rating distribution for CLSA/CLST only Universe:

Overall rating distribution: BUY / Outperform - CLSA: 64.52%; CLST only: 67.61%, Underperform / SELL - CLSA: 35.48%; CLST only: 32.39%, Restricted - CLSA: 0.00%; CLST only: 0.00%. Data as of 30 June 2017.

Investment banking clients as a % of rating category: BUY / Outperform - CLSA: 4.77%; CLST only: 0.00%, Underperform / SELL - CLSA: 2.98%; CLST only: 0.00%, Restricted - CLSA: 0.00%; CLST only: 0.00%. Data for 12-month period ending 30 June 2017.

There are no numbers for Hold/Neutral as CLSA/CLST do not have such investment rankings.

For a history of the recommendations and price targets for companies mentioned in this report, as well as company specific disclosures, please write to: (a) CLSA, Group Compliance, 18/F, One Pacific Place, 88 Queensway, Hong Kong and/or; (b) CLST Compliance (27/F, 95, Section 2 Dun Hua South Road, Taipei 10682, Taiwan, telephone (886) 2 2326 8188). © 2017 CLSA Limited and/or CLST.

© 2017 CLSA Limited, and/or CL Securities Taiwan Co., Ltd. ("CLST")

This publication/communication is subject to and incorporates the terms and conditions of use set out on the www.clsa.com website (www.clsa.com/disclaimer.html). Neither the publication/communication nor any portion hereof may be reprinted, sold, resold, copied, reproduced, distributed, redistributed, published, republished, displayed, posted or transmitted in any form or media or

by any means without the written consent of CLSA group of companies ("CLSA") and/or CLST.

CLSA and/or CLST have produced this publication/communication for private circulation to professional, institutional and/or wholesale clients only. This publication/communication may not be distributed or redistributed to retail investors. The information, opinions and estimates herein are not directed at, or intended for distribution to or use by, any person or entity in any jurisdiction where doing so would be contrary to law or regulation or which would subject CLSA and/or CLST to any additional registration or licensing requirement within such jurisdiction. The information and statistical data herein have been obtained from sources we believe to be reliable. Such information has not been independently verified and we make no representation or warranty as to its accuracy, completeness or correctness. Any opinions or estimates herein reflect the judgment of CLSA and/or CLST at the date of this publication/communication and are subject to change at any time without notice. Where any part of the information, opinions or estimates contained herein reflects the views and opinions of a sales person or a non-analyst, such views and opinions may not correspond to the published view of CLSA and/or CLST. This is not a solicitation or any offer to buy or sell. This publication/communication is for information purposes only and does not constitute any recommendation, representation, warranty or guarantee of performance. Any price target given in the report may be projected from one or more valuation models and hence any price target may be subject to the inherent risk of the selected model as well as other external risk factors. This is not intended to provide professional, investment or any other type of advice or recommendation and does not take into account the particular investment objectives, financial situation or needs of individual recipients. Before acting on any information in this publication/communication, you should consider whether it is suitable for your particular circumstances and, if appropriate, seek professional advice, including tax advice. CLSA and/or CLST do/does not accept any responsibility and cannot be held liable for any person's use of or reliance on the information and opinions contained herein. To the extent permitted by applicable securities laws and regulations, CLSA and/or CLST accept(s) no liability whatsoever for any direct or consequential loss arising from the use of this publication/communication or its contents. Where the publication does not contain ratings, the material should not be construed as research but is offered as factual commentary. It is not intended to, nor should it be used to form an investment opinion about the non-rated companies.

Subject to any applicable laws and regulations at any given time, CLSA, CLST, their respective affiliates or companies or individuals connected with CLSA /CLST may have used the information contained herein before publication and may have positions in, may from time to time purchase or sell or have a material interest in any of the securities mentioned or related securities, or may currently or in future have or have had a business or financial relationship with, or may provide or have provided investment banking, capital markets and/or other services to, the entities referred to herein, their advisors and/or any other connected parties. As a result, investors should be aware that CLSA, CLST and/or their respective affiliates or companies or such individuals may have one or more conflicts of interest. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to research reports. Details of the discloseable interest can be found in certain reports as required by the relevant rules and regulation and the full details are available at http://www.clsa.com/member/research_disclosures/. Disclosures therein include the position of CLSA and CLST only. Unless specified otherwise, CLSA did not receive any compensation or other benefits from the subject company covered in this publication/communication, or from any third party in connection with this report. If investors have any difficulty accessing this website, please contact webadmin@clsa.com on +852 2600 8111. If you require disclosure information on previous dates, please contact compliance_hk@clsa.com.

This publication/communication is distributed for and on behalf of CLSA Limited (for research compiled by non-US and non-Taiwan analyst(s)), and/or CLST (for research compiled by Taiwan analyst(s)) in Australia by CLSA Australia Pty Ltd; in Hong Kong by CLSA Limited; in India by CLSA India Private Limited, (Address: 8/F, Dalamal House, Nariman Point, Mumbai 400021. Tel No: +91-22-66505050. Fax No: +91-22-22840271; CIN: U67120MH1994PLC083118; SEBI Registration No: INZ000001735; in Indonesia by PT CLSA Sekuritas Indonesia; in Japan by CLSA Securities Japan Co., Ltd; in Korea by CLSA Securities Korea Ltd; in Malaysia by CLSA Securities Malaysia Sdn Bhd; in the Philippines by CLSA Philippines Inc (a member of Philippine Stock Exchange and Securities Investors Protection Fund); in Thailand by CLSA Securities (Thailand) Limited; in Taiwan by CLST and in the United Kingdom by CLSA (UK).

India: CLSA India Private Limited, incorporated in November 1994 provides equity brokerage services (SEBI Registration No: INZ000001735), research services (SEBI Registration No: INH000001113) and merchant banking services (SEBI Registration

No.INM000010619) to global institutional investors, pension funds and corporates. CLSA and its associates may have debt holdings in the subject company. Further, CLSA and its associates, in the past 12 months, may have received compensation for non-investment banking securities and/or non-securities related services from the subject company. For further details of "associates" of CLSA India please contact Compliance-India@clsa.com.

United States of America: Where any section is compiled by non-US analyst(s), it is distributed into the United States by CLSA solely to persons who qualify as "Major US Institutional Investors" as defined in Rule 15a-6 under the Securities and Exchange Act of 1934 and who deal with CLSA Americas. However, the delivery of this research report to any person in the United States shall not be deemed a recommendation to effect any transactions in the securities discussed herein or an endorsement of any opinion expressed herein. Any recipient of this research in the United States wishing to effect a transaction in any security mentioned herein should do so by contacting CLSA Americas.

Canada: The delivery of this research report to any person in Canada shall not be deemed a recommendation to effect any transactions in the securities discussed herein or an endorsement of any opinion expressed herein. Any recipient of this research in Canada wishing to effect a transaction in any security mentioned herein should do so by contacting CLSA Americas.

United Kingdom: In the United Kingdom, this research is a marketing communication. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research, and is not subject to any prohibition on dealing ahead of the dissemination of investment research. The research is disseminated in the EU by CLSA (UK), which is authorised and regulated by the Financial Conduct Authority. This document is directed at persons having professional experience in matters relating to investments as defined in Article 19 of the FSMA 2000 (Financial Promotion) Order 2005. Any investment activity to which it relates is only available to such persons. If you do not have professional experience in matters relating to investments you should not rely on this document. Where the research material is compiled by the UK analyst(s), it is produced and disseminated by CLSA (UK). For the purposes of the Financial Conduct Rules this research is prepared and intended as substantive research material.

Singapore: In Singapore, research is issued and/or distributed by CLSA Singapore Pte Ltd (Company Registration No.: 198703750W), a Capital Markets Services licence holder to deal in securities and an exempt financial adviser, solely to persons who qualify as an institutional investor, accredited investor or expert investor, as defined in s.4A(1) of the Securities and Futures Act. Pursuant to Paragraphs 33, 34, 35 and 36 of the Financial Advisers (Amendment) Regulations 2005 of the Financial Advisers Act (Cap 110) with regards to an institutional investor, accredited investor, expert investor or Overseas Investor, sections 25, 27 and 36 of the Financial Adviser Act (Cap 110) shall not apply to CLSA Singapore Pte Ltd. Please contact CLSA Singapore Pte Ltd (telephone No.: +65 6416 7888) in connection with queries on the report. MCI (P) 033/11/2016

The analysts/contributors to this publication/communication may be employed by any relevant CLSA entity, CLST or a subsidiary of CITIC Securities Company Limited which is different from the entity that distributes the publication/communication in the respective jurisdictions.

MSCI-sourced information is the exclusive property of Morgan Stanley Capital International Inc (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, disseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are service marks of MSCI and its affiliates. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and Standard & Poor's. GICS is a service mark of MSCI and S&P and has been licensed for use by CLSA.

EVA® is a registered trademark of Stern, Stewart & Co. "CL" in charts and tables stands for CLSA and "CT" stands for CLST estimates unless otherwise noted in the source.